17 Dec 2024 Research & Development Spotlight Series – Episode 7 Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
12 Dec 2024 Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment Investors | Therapeutics
27 Nov 2024 Peel Hunt Healthcare & Life Sciences Podcast with Christina Coughlin Investors | Podcasts and Videos | Therapeutics
08 Nov 2024 Video presentations from R&D Spotlight: ‘Next Generation of pre|CISION® Medicines’ Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
24 Oct 2024 Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Investors | Therapeutics
21 Oct 2024 Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology Investors | Therapeutics
17 Oct 2024 Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform Investors | Therapeutics
15 Oct 2024 Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer Investors | Therapeutics
10 Oct 2024 Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium Investors | Therapeutics